SEATTLE, WA — (Marketwired) — 12/14/16 — CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Medical Marijuana Inc.’s (OTC PINK: MJNA) global position in the burgeoning market for hemp-derived, cannabidiol (CBD)-based products. According to the Hemp Industry Association, annual retail sales […]

by

LOS ANGELES–(BUSINESS WIRE)–Phytecs is expanding its preclinical research program on its novel fluorinated cannabidiol, HUF-101, along with its family of related drug molecules developed by noted medicinal chemist and Phytecs Director of Global Research, Prof. Raphael Mechoulam of The Hebrew University of Jerusalem. A new preclinical study found HUF-101 effective in mice models predictive of […]

by

Please note that Epilepsy Research UK does not endorse/promote individual epilepsy treatments or pharmaceutical companies. Treatment with cannabidiol (CBD) improves the frequency and severity of seizures in children and adults with epilepsy, according to research presented at the American Epilepsy Society annual meeting in Huston, Texas. The findings are based on an open label,* expanded access […]

by

Please note that Epilepsy Research UK does not endorse/promote individual epilepsy treatments or pharmaceutical companies. Treatment with cannabidiol (CBD) improves the frequency and severity of seizures in children and adults with epilepsy, according to research presented at the American Epilepsy Society annual meeting in Huston, Texas. The findings are based on an open label,* expanded access […]

by

Please note that Epilepsy Research UK does not endorse/promote individual epilepsy treatments or pharmaceutical companies. Treatment with cannabidiol (CBD) improves the frequency and severity of seizures in children and adults with epilepsy, according to research presented at the American Epilepsy Society annual meeting in Huston, Texas. The findings are based on an open label,* expanded access […]

by

DEVON, Pa., Nov. 21, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that Armando Anido, Chairman and CEO, and other members of Company management will participate at various upcoming investor meetings and conferences in November, including:Oppenheimer Life Sciences […]

by

PULLMAN, Wash., July 28 (UPI) — The breakdown of muscle often accompanies chronic or long-term disease, making disease worse and sometimes hastening death, and doctors have no way to stop or slow it. Researchers at Washington State University devised a method of delivering gene therapy to stop muscle wasting without affecting other functions of the […]

by

It’s been an eventful year for marijuana stocks, with activity led by GW Pharmaceuticals‘ (NASDAQ: GWPH) and Corbus Pharmaceuticals‘ (NASDAQ: CRBP) clinical trial data releases and Insys Therapeutics‘ (NASDAQ: INSY) approval of its first cannabinoid product, Syndros. Continue Reading Below Let’s take a look back and see what the future holds for marijuana stocks. Image […]

by

Speakers include world-renowned physicians Meeting to begin at 8:00 am ET; webcast will be available DEVON, Pa., Dec. 08, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will host its first Clinical Research Day on […]

by

GW Pharmaceuticals recently presented positive results from two Phase 3 clinical trials evaluating its lead cannabidiol therapeutic candidate, Epidiolex, in patients with lennox-gastaut syndrome (LGS) and Dravet syndrome (DS), two treatment-resistant epilepsy syndromes. The presentations took place during the American Epilepsy Society (AES) Annual Meeting in Houston, Texas Dec. 2-6. Epidiolex is an oral formulation of pure […]

by